Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa

Journal of Chemotherapy

Volumn 26, Issue 2, 2014, Pages 122-124

  Luque, Sonia ^a   Sorli, Luisa ^a   Li, Jian ^b   Collado, Silvia ^a   Barbosa, Francesc ^a   Berenguer, Nuria ^c   Horcajada, Juan Pablo ^a   Grau, Santiago ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSIDAD SAN JORGE   (Spain)

Author keywords

Colistin; Haemodialysis; Pharmacokinetics; Pseudomonas aeruginosa; Renal insufficiency

Indexed keywords

CEFTAZIDIME; COLISTIMETHATE; COLISTIN; IMIPENEM; LEVOFLOXACIN; POLYMYXIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; CASE REPORT; DEATH; END STAGE RENAL DISEASE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; TREATMENT FAILURE; URINARY CATHETER; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RENAL REPLACEMENT THERAPY;

AGED; ANTI-BACTERIAL AGENTS; COLISTIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; POLYMYXINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RENAL DIALYSIS;

EID: 84895821657     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000104     Document Type: Article

References (10)

1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589-601.
2. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1953-58.
3. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167-75.
4. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother. 2002;46: 3304-7.
5. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically-ill patients from a multi-center study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-94.
6. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2005;49:4814-5.
7. Marchand S, Frat JP, Petitpas F, Lemaitre F, Gobin P, Robert R, et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother. 2006; 8:1836-7.
8. Goodwin NJ, Friedman EA. The effects of renal impairment, peritoneal dialysis, and haemodialysis on serum sodium colistimethate levels. Ann Intern Med. 1968;68:984-94.
9. Greenberg PA, Sanford JP. Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate. Ann Intern Med. 1976;66:465-70.
10. Ratjen JF, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:306-11.